It has been about a month since the last earnings report for Catalyst Pharmaceutical (CPRX). Shares have added about 14.7% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Catalyst due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended upward during the past month.
The consensus estimate has shifted 10.87% due to these changes.
VGM Scores
At this time, Catalyst has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with an F. However, the stock was allocated a grade of B on the value side, putting it in the second quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of A. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending upward for the stock, and the magnitude of these revisions looks promising. Notably, Catalyst has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
Catalyst is part of the Zacks Medical - Drugs industry. Over the past month, Ionis Pharmaceuticals (IONS), a stock from the same industry, has gained 1.2%. The company reported its results for the quarter ended December 2024 more than a month ago.
Ionis Pharmaceuticals reported revenues of $227 million in the last reported quarter, representing a year-over-year change of -30.2%. EPS of -$0.66 for the same period compares with -$0.06 a year ago.
Ionis Pharmaceuticals is expected to post a loss of $1.07 per share for the current quarter, representing a year-over-year change of -9.2%. Over the last 30 days, the Zacks Consensus Estimate has changed -2.6%.
Ionis Pharmaceuticals has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of F.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Catalyst Pharmaceuticals, Inc. (CPRX): Free Stock Analysis Report Ionis Pharmaceuticals, Inc. (IONS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
